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The trisomy 8 found in malignancies may derive from a constitutional trisomy 8 mosaicism (CT8M), and in these cases the
trisomy itself may be regarded as the first mutation in a multistep carcinogenetic process. To assess the frequency of CT8M
in hematological dysplastic and neoplastic disorders with trisomy 8, an informative sample of 14 patients was collected. The
data ascertained included chromosome analyses of fibroblast cultures and of PHA-stimulated blood cultures in patients with
normal blood differential count, as well as possible CT8M clinical signs. One patient showed trisomy 8 in all cell types analyzed
and undoubtedly has a CT8M; a second patient consistently showed trisomy 8 in PHA-stimulated blood cultures when no
immature myeloid cells were present in blood and should be considered as having CT8M; a third patient, with Philadelphia-
positive chronic myelocytic leukemia, was more difficult to interpret, but the possibility that she had CT8M is likely. A few
clinical signs of CT8M were also present in these three patients. Our data indicate that the frequency of CT8M in
hematological dysplastic and neoplastic disorders with trisomy 8 is approximately 15–20%. © 2002 Wiley-Liss, Inc.
In 1996, we postulated that trisomy 8 found in
neoplasms, particularly in hematological malignan-
cies, may be derived from a constitutional trisomy
8 mosaicism (CT8M) (Seghezzi et al., 1996). Tri-
somy 8 was the first mutation of the multistep
carcinogenesis in the three patients reported and,
most likely, in another eight patients reviewed
from the literature. We noted that eight out of the
12 documented cases of CT8M developing a ma-
lignancy had myeloproliferative disorders (Dane-
sino et al., 1998), which is not unexpected, as tri-
somy 8 is particularly frequent in these
malignancies (Mitelman et al., 2001).
We have collected from our laboratory files all
the patients with myelodysplastic syndromes
(MDS), acute leukemia (AL), or myeloproliferative
disorder (MD) with trisomy 8 in order to establish
how frequently they arise in CT8M. We tried to
obtain three types of data which might be able to
demonstrate CT8M: 1) results of chromosome
analyses of fibroblasts; 2) results of chromosome
analyses of PHA-stimulated blood cultures in pa-
tients with a normal blood differential count; and 3)
possible clinical signs of CT8M, which we
searched for personally, based on the most reliable
available list (Schinzel, 1994). In total, 14 patients
were retrieved, of which one (case 7) has been
reported previously. The clinical and cytogenetic
findings are summarized in Table 1.
Chromosome analyses of fibroblasts provided ev-
idence for CT8M in case 11, whereas PHA-stimu-
lated blood cultures suggested CT8M in case 8.
The combined results of chromosome analyses of
bone marrow (BM) and peripheral blood (PB) of
case 7 indicated the possibility that this patient also
had a CT8M. Table 2 gives the details of relevant
chromosome analyses performed in these three pa-
tients.
A search for clinical signs of CT8M was per-
formed in 13 of the 14 patients, excluding case 4,
who was affected with Down syndrome. We did
not find any significant features of CT8M in any of
the patients, although some minor signs were often
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present. It has been known since 1980, however,
that CT8M may be associated with a near-normal
phenotype and a normal IQ (Chandley et al., 1980).
The wide variation of phenotypes in CT8M has
been extensively discussed (Seghezzi et al., 1996;
Danesino et al., 1998; Habecker-Green et al.,
1998), and we searched for CT8M signs only to
obtain possible ancillary evidence.
Below, data favoring CT8M in patients 7, 8, and
11 are summarized.
Patient 7
We previously reported this patient, affected
with chronic myelocytic leukemia (CML), due to
her peculiar cytogenetic pattern, with cells with the
Philadelphia chromosome (Ph), cells with the Ph
and trisomy 8, and cells with trisomy 8 without the
Ph (Casali et al., 1992). Three similar cases, with
Ph-negative trisomic 8 clones in patients with Ph-
positive CML, have been reported since then (Bil-
hou-Nabera et al., 1993; Ariyama et al., 1995; Shep-
herd et al., 1996). In these cases, however, no cells
were present with the trisomy 8 superimposed on
the Ph, as in our patient (Table 2), a finding asso-
ciated with accelerated/blastic phase (BP) of CML.
Ariyama et al. (1995) also provided evidence that in
their case the trisomic 8 clone showed no BCR/ABL
rearrangement.
In our previous article (Casali et al., 1992), we
suggested several explanations for this cytogenetic
feature. One, which we deem very unlikely, is a
retromutation to correct the Ph translocation in a
subclone derived from the one with Ph and trisomy
8. We favored the possibility of a secondary MDS
in a clone independent from CML, which by
chance had acquired the same anomaly. Bilhou-
Nabera et al. (1993) agreed with this explanation.
We must admit, however, that no signs of MDS
were ever noted in the bone marrow of our patient,
or documented in the other three mentioned
above, and that our patient entered a BP only in
July 1997, 11 years after CML diagnosis and 7 years
after the finding of the additional trisomy 8. Again,
secondary MDS is infrequent in the course of
CML, and the severe pancytopenic phase of our
patient (Casali et al., 1992) may well be explained
by prolonged a-interferon (IFN) therapy. CT8M is
a third possible explanation for these observations,
and it is certainly compatible with a normal or
near-normal phenotype, as was the case in our
patient: the only argument against CT8M would
be that the two Ph-positive clones, with and with-
out trisomy 8, should imply an origin of CML in at
least two different marrow cells, constitutionally
with two and three chromosomes 8. CML is strictly
considered monoclonal in origin, and even in sub-
TABLE 1. Patients Included in the Study
Patient Age/Sex Diagnosisa Significant 18 karyotype—Materialb
Available data on
PB-PHAb
cytogenetics
CT8Mc
phenotype
FBb
cytogenetics
1—SMG 79/F MDS 48,XX,18,19[15]—BM 2 1 1
2—SA 54/M AML-M4 47,XY,18[19]/46,XY[1]—BM 1 1 1
3—MB 66/M AML-M2 47,XY,18,inv(9)[24]—BM 1 1 1
4—CDd 1/M ALL 49,XY,18,121“c”,121[20]/47,XY,121“c”[5]—BM
49,XY,18,121“c”,121[8]/48,XY,18,121“c”
[2]—PB
1 1 1
5—RT 69/F MDS-S 47,XX,18[8]/46,XX[9]—BM 1 1 1
6—MI 24/M RA 47,XY,18[3]/46,XY[37]—BM 1 1 1
7—TM 61/F CML 47,XX,18,t(9;22)[3]/47,XX,18[3]/46,XX,t(9;22)[7]/
46,XX[9]—BM
1 1 2
8—FF 3/M RA 47,XY,18[20]—BM 1 1 1
9—ME 58/F CML-BP 47,XX,18,t(9;22)[12]/46,XX[1]—PB 1 2 1
10—MA 72/F MDS 47,XX,18[13]—BM 1 1 1
11—BCI 25/F RA 47,XX,18[24]/46,XX[1]—BM 1 1 1
12—BC 76/F PV 47,XX,18[3]/46,XX[40]—BM 1 2 1
13—CV 77/M MDS 46,X,2Y,18[7]/45,X,2Y[19]—BM 2 2 1
14—FA 12/M AML-M2 47,XY,18[22]—BM 1 1 1
aMDS 5 myelodysplastic syndrome; AML 5 acute myeloblastic leukemia; M4, M2 5 FAB type; ALL 5 acute lymphoblastic leukemia; MDS-S 5
secondary MDS; RA 5 refractory anemia; CML 5 chronic myelocytic leukemia; BP 5 blastic phase; PV 5 polycythemia vera.
bBM 5 bone marrow direct preparations and 24–48 hr cultures; PB 5 peripheral blood unstimulated cultures; PB-PHA 5 PHA-stimulated blood
cultures; FB 5 fibroblasts from skin or other tissue biopsy.
cCT8M 5 constitutional trisomy 8 mosaicism.
dAffected with Down syndrome.
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jects with a constitutional chromosome mosaicism
it was demonstrated that it was restricted to one
cell population (Chaganti et al., 1982; Oguma et al.,
1989).
Five patients with Ph-positive CML who devel-
oped Ph-negative clones with abnormalities differ-
ent from trisomy 8 have been reported (Shepherd
et al., 1996; Fayad et al., 1997). Thus, a total of nine
Ph-positive CML cases are known in which a Ph-
negative clone with different chromosome anoma-
lies was found, and in all cases after IFN therapy
(Table 3). A specific effect of IFN was therefore
suspected, with the possible development of MDS,
but although IFN in CML seems to lead to Ph-
positive clones with aberrant chromosomal evolu-
tion patterns (Johansson et al., 1996), Fayad et al.
(1997) concluded that it is not possible to attribute
the origin of abnormal Ph-negative clones to IFN
treatment. It is noteworthy that MDS was docu-
mented only in one of these patients (Table 3). A
TABLE 2. Results of Chromosome Analyses in Patients 7, 8, and 11
Date Materiala Karyotype
Case7—TM
18.06.90 BM 46,XX,t(9;22)(q34;q11)[7]/47,XX,t(9;22),18[3]/47,XX,18[3]/46,XX[9]
16.07.90 BM 46,XX,t(9;22)(q34;q11)[17]/47,XX,t(9;22),18[6]/46,XX[5]
PB-PHA 46,XX,t(9;22)(q34;q11)[1]/47,XX,18[2]/46,XX[32]
15.05.96 PB 46,XX,t(9;22)(q34;q11)[14]
PB-PHA 46,XX,t(9;22)(q34;q11)[20]/46,XX[40]
Case 8—FF
12.10.92 PB-PHA 47,XY,18[5]/46,XY[62]
12.01.93 PB-PHA 47,XY,18[7]/46,XY[93]
PB-DEB 47,XY,18[1]/46,XY[50]
16.04.93 BM 47,XY,18[5]/46,XY[8]
07.06.93 BM 47,XY,18[20]
30.06.93b BM 46,XX[30]
14.12.93 PB-PHA 46,XX[30]
SFc 46,XY[50]
SFd 46,XY[50]
Case 11—BC
02.12.98 BM 47,XX,18[24]/46,XX[1]
24.02.99 BM 47,XX,18[21]/46,XX[5]
02.03.99 PB-PHA 47,XX,18[14]/46,XX[6]. nuc ish 8cen(PZ8.432)[290]/(PZ8.433)[210]
12.05.99 PB-PHA 47,XX,18[15]/46,XX[56]
12.07.99 PB-PHA 47,XX,18[8]/46,XX[12]
PB-LPS 47,XX,18[1]/46,XX[2]
SF 47,XX,18[80]/46,XX[40]
aBM 5 bone marrow direct preparations and 24–48 hr cultures; PB-PHA 5 PHA-stimulated peripheral blood cultures; PB 5 unstimulated peripheral
blood cultures; SF 5 skin fibroblast culture; PB-DEB 5 PHA-stimulated peripheral blood cultures with diepoxybutane (0.01 g/ml) added; PB-LPS 5
peripheral blood cultures stimulated with E. coli lipopolysaccharide.
bAfter allogeneic bone marrow transplantation from a female donor.
cFirst growth halo.
dSecond growth halo.
TABLE 3. Reported Cases With Chromosome Changes (CC) in Ph-negative Cells in the Course of Ph-positive CML After
a-Interferon Therapy
Patient CC in Ph 2 cells
Presence of the same
CC in Ph 1 cells
Evidence
of MDS Reference
Casali et al., 1992—present case n. 7 18 1 2 5
Bilhou-Nabera et al., 1993 18 2 2 6
Ariyama et al., 1995 18 2 2 7
Seghezzi et al., 1996—pt. 3 27 2 2 8
Seghezzi et al., 1996—pt. 4 18 2 2 8
Seghezzi et al., 1996—pt. 5 5q- 2 2 8
Fayad et al., 1997—pt. 1 del(5)(q13q34), clonal evolution 2 1 11
Fayad et al., 1997—pt. 2 18p1, 26 2 2 11
Fayad et al., 1997—pt. 3 del(11)(q21q23) 2 2 11
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Ph-positive clone with the same anomaly found in
Ph-negative cells was present only in our patient
(Table 3).
Two efforts to demonstrate CT8M in our patient
by means of chromosome analysis of fibroblasts
cultured from a skin biopsy and from a biopsy of
uterine mucosa unfortunately failed. The most
plausible explanation for the results obtained is
that our patient had a CT8M, that the Ph arose in
a trisomic bone marrow cell at the onset of the
disease, and that the trisomy was then corrected to
disomy in a subclone. If this is true, the trisomy 8
would not indicate a progression towards BP.
In order to explain cases such as those listed in
Table 3, Fayad et al. (1997) suggested the possi-
bility that, since CML is a stem-cell disorder, the
selective Ph suppression obtained with IFN ther-
apy may allow the expansion of other clones orig-
inating from “abnormal Ph-negative stem cells”
(Shepherd et al., 1997), which are usually masked
by proliferating Ph-positive cells. According to our
interpretation of CT8M, the stem-cell abnormality
is likely to be the constitutional trisomy 8.
Patient 8
This 3-year-old child was investigated due to
anemia, and a trisomy 8 was found in PHA-stimu-
lated blood cultures, performed also with diepoxi-
butane (DEB) to search for the chromosome break-
age syndrome Fanconi’s anemia. A few months
later, refractory anemia (RA) was diagnosed, with
subsequent evolution into RA with excess of blasts
in transformation (RAEB-T). He underwent an al-
logeneic bone marrow transplantation. Chromo-
some analysis of fibroblasts cultured from a skin
biopsy did not reveal any trisomic 8 cells (Table 2).
While the finding of trisomy 8 in these cells would
be conclusive for CT8M, its absence does not ex-
clude mosaicism because the distribution of the
different cell lines in tissues of a subject with a
chromosome mosaicism is unpredictable.
The phenotype of this child was evaluated
twice, when he was 4 and 5 years old, and judged
normal, as was mental development, with only a
few possible CT8M signs.
Our conclusion of CT8M relies on the consistent
presence of trisomic cells at the analyses made on
PHA-stimulated blood cultures (also in the pres-
ence of DEB) at onset on two different occasions
before RA diagnosis (Table 2), when differential
blood counts did not include any immature cells.
Two hematologists independently reviewed the
original blood smears of the same dates of chromo-
some analyses, and they confirmed the normal re-
sults.
Patient 11
Slightly reduced levels of neutrophils and eryth-
rocytes in peripheral blood, but absence of any
other symptoms, were noted in this patient, who
presented at the age of 9 years. RA was diagnosed
at 25 years of age when chromosome analyses of
bone marrow cells revealed a trisomy 8 (Table 2).
Cells with trisomy 8 were found in all tissues ex-
amined: PHA-stimulated lymphocytes, LPS-stim-
ulated peripheral blood culture, and fibroblasts
from a skin biopsy (Table 2). A fluorescence in situ
hybridization (FISH) analysis on interphase nuclei,
with a centromere-specific chromosome 8 probe,
was also done to ascertain better the proportion of
trisomic cells. The patient was a university student,
and her clinical phenotype was normal, with only
some possible CT8M signs. The cytogenetic and
FISH results obtained are summarized in Table 2
and are compatible with CT8M.
Thus, 3 out of 14 cases of MDS, AL, and MD
characterized by trisomy 8 originated from a
CT8M—a frequency of 21%. If we exclude patient
7, whom we believe to be CT8M, but with less
solid evidence than for patients 8 and 11, we would
conclude that the frequency was 2/14 (14%). Ob-
viously, our sample is too small to draw any firm
conclusions, but we may postulate that the propor-
tion of MDS/AL/MD which harbor a supposed
acquired trisomy 8 and are in fact CT8M is 15–
20%. In these cases, as in the ones previously
reported by us (Seghezzi et al., 1996), the consti-
tutional trisomy 8 would be the first mutation of
multistep carcinogenesis.
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